SCART study: selumetinib as potential treatment for HIV-related KS
Simon Collins, HIV i-Base
SCART is a UK phase 2 study using selumetinib to treat HIV-related Kaposi’s Sarcoma (KS) in people on ART with progressive KS.
Selumetinib is a mitogen-activated protein kinase (MEK) inhibitor currently in phase 3 studies to treat other types of cancer. MEK is a protein involved in signaling for cell division.
SCART is a phase 2 study because there is less information on the use to treat KS. Phase 1 of the study was used to decide the best dose and to check for any early safety concerns in HIV positive people.
Phase 2 is now looking at how effectively KS responds to treatment in 25 people with HIV-related KS that has become worse during the last six months. Selumetinib is dosed at 75 mg twice-daily (2 x 3 tablets per day, total 6 tablets per day). The study involves safety and monitoring visits to the hospital every 21 days.
The SCART study is being run at five UK hospitals.
- Weston Park Hospital, Sheffield
- Chelsea and Westminster Hospital, London
- Royal Sussex County Hospital, Brighton
- The Beatson West of Scotland Cancer Centre, Glasgow
- Christie Hospital, Manchester
More detailed information:
For further information or enquiries about the SCART trial please contact:
The Coordinating Centre for SCART is the Cancer Research Clinical Trials Unit (CRCTU), University of Birmingham.
This trial is supported by AstraZeneca, Cancer Research UK, Experimental Cancer Medicine Centre (ECMC), National Institute for Health Research Cancer Research Network (NCRN), Sheffield Teaching Hospitals NHS Foundation Trust and the University of Birmingham.